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Background & Hypothesis: ICDs with smaller capacitors (C) and less maxi-
mum energy (E) output than today's ICDs might allow implantation of en-
docardiallead systems with an acceptable safety margin in some patients.
Using small capacitors that deliver shorter duration (SD) waveforms would
significantly reduce ICD size.
Methods: Intraoperatively, standard (STD) and SO biphasic (60:40, 80%
tilt) waveforms were compared using a cross-over study design:
In 30 patients (age: 59 ± 10; male: 24, CAD: 22, DCM: 4, EF 42 ± 15%,
amiodarone: 8), the defibrillation threshold (OFT) was determined using a
step-down protocol (20, 15, 10,8, 5, 3, 2, 1 J) during ICD implantation. Pa-
tients were randomized to receive an endocardial defibrillation lead-alone
lTV; Endotak® 0072, n = 15) or in combination with a subcutaneous defibril-
lation array (SC, Endotak® 0048, n = 15).
Results: The SO waveform defibrillated with energies ::;10 J in 67% of the
patients with TV and 80% of the patients with SC.
Alive (N = 1321) Dead (N ~ 1847) X2
Characteristcs
N(%)
Age Iyrs) 634 ± 10.9 698 ±104 2524
Current Smoker 567 (43%) 407 (26%) 92.4
Killip class 1 or 2 on arrival 1140187%) 1325 (81%) 67.6
Infarct location anterior 570 (43%) 931 (57%) 57.7
PriorMI 255 (19%) 488 (30%) 440
Weight (kg) 780 ± 162 74.1 ± 152 400
Height (em) 170.9 ± 99 168.0 ± 9.7 38.4
Admission pulse 79.3±21.1 84.5 ± 22.6 369
Diabetes 187 (14%) 369 (23%) 35.4
Time to Rx (hrs) 2.99 ± 1.64 3.32 ± 178 33.8
Prior angina 480137%) 751 (47%) 29.4
Cardiogenic shock during acute myocardial infarction is associated with a
marked increase in mortality. In GUSTO I Trial, the mortality in cardiogenic
shock patients was 59%. The ability to predict mortality in these patients
might help to devise better strategies. Baseline characteristics of 1968 car-
diogenic shock patients in GUSTO were assessed in relationship to 30 day
outcome:
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Predictors of Mortality in Cardiogenic Shock: The
GUSTO Experience
David R. Holmes, Peter B. Berger, Eric Bates, Lynn Woodlief, Eric J. Topol,
Robert Califf, GUSTO Investigators. Mayo Clinic, Rochester, MN
Combining these baseline characteristics in a multivariate model provides
very good discrimination of prediction of mortality.
Conclusion: Baseline characteristics can identify patients at high risk of dy-
ing associated with cardiogenic shock. Since previous controlled trials have
not demonstrated efficacy of thrombolysis in cardiogenic shock, these fea-
tures may set up preferential triage to primary percutaneous transluminal
coronary angioplasty or other aggressive reperfusion strategies.
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DefibrillatorWaveform
STD
SD
DFT All IJI TVIJI SCIJI All IVI
STD 9.5 ± 4.9 11.3 ± 4.4 7.7 ± 3.9 322 ± 80
SD 10.3 ± 4.1 11.2 ± 46 94 ± 3.3 411 ± 80
P n.s. n.s. n.s. <0.0001
The significantly higher voltages of the SO waveform did not significantly
reduce the the sensing electrogram amplitude 6 s after a 15 J shock com-
pared to the STD waveform (0.92 ± 0.22 vs. 0.91 ± 0.17).
Conclusions: A shorter duration waveform delivered by smaller capacitors
with less maximum energy output yielded a 10 J safety margin for endocar-
dial lead-alone defibrillation in approx. 67% (resp. 80% combined with SCI
of the patients tested. Despite higher voltages for the same energy output
reductions in post-shock electrogram amplitude were not larger than those
seen with standard capacitors.
3:15
Increased Action Potential Prolongation by Low
Voltage Biphasic versus Monophasic Field Stimuli
Robert J. Sweeney, Robert M. Gill, Philip R. Reid. Eli Ully and Company- Indianapolis,
IN
In an in-vitro model for defibrillation, we compared action potential prolon-
gation (APP) by monophasic (MONO) and biphasic IBI) field stimulus shocks
in epicardial tissue strips from 10 dogs. Strips were paced at one end while
cellular impalements were maintained in the center (cell A) to measure APP
and at the other end (cell B) to determine if shocks produced propagated
activations. Rectangular shocks (0.5 to 10 V/cm) were delivered with MONO
(8 ms) or BI (4.8/3.2 ms) waveforms at times ranging from 44% to 112% of
the APD90 of cell A. Recordings were made during 3975 shocked and 2578
control action potentials. APP was the % increase in shocked repolarization
time relative to the interlaced controls.
While weaker MONO and BI shocks produced propagated activations, the
threshold intensity ABOVE which shocks did NOT produce activations was
25.9% lower (p < 0.0005) for BI (2.78 V/cm) versus MONO (3.75 Vfcm). At
most intensities and timings, MONO produced more APP than BI. However,
for 2 to 4 V/cm shocks at 90% to 100% of APD90, BI produced more APP
than MONO (36.9% versus 17.7%, P < 0.0001) shocks.
Thus, increased defibrillation efficacy of BI waveforms may result from a
greater APP by BI in the low-voltage gradient regions of the heart during
defibrillation.
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Myocardial infarction (MI) patients with advanced age, multivessel disease
or ventricular dysfunction continue to have a poor prognosis despite reper-
fusion therapy. Furthermore, the majority of deaths from MI occur within
the first 48 hours, thus risk stratification and therapeutic interventions ide-
ally should occur acutely. The PAMI-2 study has prospectively evaluated the
hypotheses that 1) emergency catheterization with primary PTCA may allow
acute risk stratification and 2) clinical outcome, ventricular function and in-
farct vessel patency will be improved by balloon pumping in patients iden-
tified to be high risk. MI patients who presented 0-12 hrs underwent emer-
gency catheterization and PTCA and were stratified as high risk if one of the
following was present: age>70 yrs, vein graft occlusion, 3 vessel disease,
ejection fraction <45%, suboptimal PTCA result or if malignant arrhythmias
persisted post PTCA. High risk patients were randomized to receive or not
receive an intra aortic balloon pump (IABP) for 48 hrs. Catheterization was
repeated at day 7 to determine infarct vessel patency and improvement in
ventricular function. At 6 weeks a rest and exercise radionuclide ventriculo-
gram was performed. To date, 320 patients have been enrolled, 175 of which
have complete data available for analysis. The reasons for high risk status in-
clude: advanced age 38%, poor LV function 55%, 3 vessel disease 37%, vein
graft occlusion 6%, suboptimal PTCA 9%, and arrhythmias 5%. Despite the
high risk status, in-hospital outcomes have been favorable: death 2.9%, re-
current MI 5.8%, stroke 1.2%, angiographic reocclusion 5.8%, heart failure
19.1 % and combined events 26.6%. Thus "high risk" patients treated with
primary PTCA ± balloon pumping appear to have a good prognosis. Whether
the improved outcome is due to balloon pump support or simply due to ag-
gressive mechanical revascularization will be determined in the entire cohort
by March 1995.
